Cytokinetics (CYTK) Director B. Lynne Parshall Sells 5,000 Shares

What Happened B. Lynne Parshall, a director of Cytokinetics, reported an open-market sale of 5,000 shares on 2026-09-01 at $71.48 per share, generating proceeds of $357,400. This was a sale (transaction code S), which is often a routine insider disposition rather than a purchase signal.

Key Details

• Transaction date and price: 2026-09-01 — 5,000 shares sold at $71.48 each.
• Total proceeds: $357,400.
• Shares owned after transaction: Not specified in the data provided on this filing.
• Filing: Form 4 filed with SEC on 2026-09-01 (accession 0001061983-26-000091); filing date matches the transaction date, with no indication of lateness in the provided record.
• Notes: Transaction reported as an open-market sale; no 10b5-1 plan, tax-withholding, or other footnotes were provided in the supplied details.

Context Open-market sales by directors are common and may reflect routine portfolio management, tax or liquidity needs, or other personal reasons — they do not by themselves indicate the company’s outlook. Purchases by insiders typically carry more weight for assessing insider sentiment. Parshall is listed as a company director (not reported as a 10% owner in the supplied information).